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P2X7 receptors are important in the regulation of inflammatory responses and immune responses to 
intracellular pathogens such as Mycobacterium tuberculosis and Toxoplasma gondii. enhancement of 
P2X7 receptor responses may be useful in pathogen clearance particularly in individuals with defective 
microbial killing mechanisms. Ginsenosides from Panax ginseng have been discovered to act as 
positive allosteric modulators of P2X7. Here we describe a novel modulator binding site identified by 
computational docking located in the central vestibule of P2X7 involving S60, D318, and L320 in the 
lower body β-sheets lining the lateral portals. Potentiation of ATP-mediated responses by ginsenosides 
CK and Rd caused enhanced ionic currents, Ca2+ influx and YOPRO-1 uptake in stably transfected 
HEK-293 cells (HEK-hP2X7) plus enhanced cell death responses. Potentiation of ATP responses by CK 
and Rd was markedly reduced by mutations S59A, S60A, D318L and L320A supporting the proposed 
allosteric modulator binding site. Furthermore, mutation of the conserved residues S60 and D318 led 
to alterations in P2X7 response and a higher sensitivity to ATP in the absence of modulators suggesting 
residues in the connecting rods play an important role in regulating P2X7 gating. Identification of this 
novel binding site location in the central vestibule may also be relevant for structurally similar channels.
P2X7 is an ATP-gated ion channel expressed on various immune cell populations including monocytes and 
macrophages1. P2X7 activation results in the activation of the NLRP3-caspase 1 inflammasome2, release of 
pro-inflammatory mediators (e.g. IL-1β, IL-18)3, shedding of transmembrane proteins (e.g. CD62L, CD23)4, 
and occurrence of cell death5. Moreover, P2X7 is implicated in immunity to intracellular pathogens such as 
Mycobacterium tuberculosis and Toxoplasma gondii amongst others making it a potential target for the modula-
tion of the immune response6,7.
Ginseng has been utilised throughout Asia for centuries where it is considered a ‘panacea’, promoting lon-
gevity and treating many diseases, although the exact mechanisms by which ginseng can exert these biological 
effects are not fully understood8,9. The ginseng root extract contains a complex mixture of bioactive compounds 
such as polysaccharides, glycolipoproteins, and polyacetylenic alcohols, however the most extensively studied 
compounds are the ‘steroid-like’ dammarane triterpenoid glycosides termed ginsenosides8. Ginsenosides can 
be further divided into the protopanaxadiols (e.g. Rb1, Rb2, Rc, Rd, Rg3, Rh2), and the protopanaxatriols (e.g. 
Re, Rf, Rg1, Rg2, Rh1), based upon whether sugar moieties are attached to carbon-3 (diols) or carbon-6 (triols). 
Metabolism of ginsenosides in the gut by microbial flora species results in the formation of readily absorbable 
metabolites including the ginsenoside compound K (CK)10. Ginsenosides have been demonstrated to modulate a 
plethora of immune cell functions such as phagocytosis, the function of inflammatory enzymes, the production 
of both pro- and anti-inflammatory cytokines, the modulation of intracellular signalling pathways, and regulation 
of the inflammasome9. Moreover, there is increasing evidence of the potential antimicrobial properties of ginseng, 
with ginsenosides providing protection against viruses (HIV, influenza, respiratory syncytial virus), bacteria (E. 
coli, Staphylococcus aureus, Brucella abortus, Pseudomonas aeruginosa) and fungi (Candida albicans)9,11,12.
1School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, United Kingdom. 2School 
of Medical Sciences, RMIT University, Bundoora, VIC, 3083, Australia. 3Present address: Department of chemistry 
& Biotechnology, Swinburne University of technology, Hawthorn, Vic, Australia. correspondence and requests for 
materials should be addressed to L.S. (email: l.stokes@uea.ac.uk)
Received: 13 August 2018
Accepted: 29 January 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:3231  | https://doi.org/10.1038/s41598-019-39771-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
We recently identified that the activity of P2X7 receptors could be modulated by protopanaxadiol ginseno-
sides such as CK, Rd, Rb1 and Rh213. These chemicals could enhance the action of the physiological agonist ATP, 
increasing both the sensitivity and the maximum response of P2X7 to agonist, thus defining the ginsenosides as 
positive allosteric modulators13. To date, there have been few positive allosteric modulators (PAMs) identified 
for P2X7 including clemastine, polymyxin B, ivermectin and tenidap14–16 and currently nothing is known about 
their molecular binding sites. Much more is known about negative allosteric modulator binding to P2X7 with a 
detailed allosteric binding site recently being described for AZ10606120 that may also accommodate other antag-
onists including JNJ-47965567, A804598, and A74000317,18. Most of what we know about P2X receptor structure 
comes from the crystal structures of closed and open state zebrafish P2X4 (zfP2X4), giant panda P2X7 (pdP2X7) 
and human P2X3 receptors17,19 plus detailed mutagenesis studies investigating ectodomain and transmembrane 
domain movements18,20–22. Our aim in this study was to identify the putative molecular binding site for ginseno-
side PAMs on the P2X7 receptor using a molecular modelling approach combined with site-directed mutagenesis. 
We describe a novel modulator binding site located in the central vestibule region of P2X7 involving two β-sheets 
in the lower body region enclosing this cavity. We demonstrate that mutations of two key residues, D318 and 
L320, abolished potentiation of P2X7 responses by the ginsenosides CK and Rd.
Results
Identification of a putative ginsenoside binding pocket by molecular modelling. We previously 
demonstrated that ginsenoside Rd and the major in vivo metabolite CK, act as positive allosteric modulators of 
human P2X7 receptors requiring the presence of agonist (ATP) for their action. This, together with data suggest-
ing pre-treatment with P2X7 antagonists such as AZ10606120 could prevent P2X7 opening even in the presence 
of CK13 led to the hypothesis that ginsenosides may bind to the open ATP-bound conformation of P2X7. To 
investigate this we generated homology models of human P2X7 (hP2X7) based upon the closed and open states of 
zfP2X4 (pdb 3H9V and 4DW1)19,23 and the closed state of pdP2X7 (pdb 5U1L)17. Model building and preliminary 
docking of the ginsenosides CK and Rd to human P2X7 was carried out using Swissmodel and Autodock Vina 
respectively, as previously described for P2X424. Subsequent analysis to further define the binding pocket was 
performed using consecutive runs of Sitemap software and docking calculations with Glide. The best predicted 
binding site for ginsenosides is located within the central vestibule of hP2X7 in a large hydrophobic cleft lined 
by β-sheets that define the lower body wall of the trimeric channel (Fig. 1). This novel binding pocket could be 
defined as being inter-subunit since interactions are made with residues in the β2-sheet on one subunit and resi-
dues in the β-14 sheet on the adjacent subunit (Fig. 2A,B)) thus connecting the post-TM1 region on one subunit 
with the pre-TM2 region on the adjacent subunit. Three internal loops at the top of the central vestibule (one from 
Figure 1. Ginsenosides bind to the central vestibular region of P2X7. Representation of a homology model of 
hP2X7 trimer in the open state with ginsenoside CK docked in the central vestibular region. Each subunit is 
differentially coloured (green, cyan, magenta). Panels show a zoom-in and rotated view of the binding site from 
the inside of the cavity facing outwards (rotation of 180°). Surface rendered images are shown to visualise the 
binding pocket for CK and Rd on hP2X7. Ligands and side chains are represented as sticks with all hydrogen 
atoms omitted for clarity. Two-dimensional chemical structures of CK and Rd are also displayed with carbon 
atoms labelled in red.
3Scientific RepoRts |          (2019) 9:3231  | https://doi.org/10.1038/s41598-019-39771-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
each subunit) guard the upper boundary of this lower body cavity (Fig. 2A,B) and connect the lower and upper 
body regions.
Induced fit docking calculations using Glide revealed two elements to the putative ginsenoside binding 
site; a glucose-specific subsite located close to the top of the central vestibule cavity and a hydrophobic cleft 
co-ordinating the steroid backbone of the ginsenosides (Figs 1 and 2C). All protopanaxadiol ginsenosides with 
activity at P2X7 could be docked into the same binding pocket on the open hP2X7 model (Fig. S1).
We focused on elucidating the binding of CK and Rd in detail as these have the highest positive modula-
tor activity at hP2X713. These two ginsenosides have highly similar structures with a single glucopyranose ring 
attached to carbon-20 (Fig. 1) although Rd has an additional disaccharide moiety attached to carbon-3. The 
binding of the glucopyranose ring of CK to hP2X7 makes hydrogen bond interactions with residues S60, N100 
and D318 (Fig. 2C). In particular it is the hydroxyl groups on carbons 2′ and 3′ of the glucopyranose moiety that 
interact with the COO− group of D318 whilst a hydroxyl group on carbon-4′ makes a hydrogen bond with the 
amide oxygen of the N100 sidechain. Further interactions appear to exist between the hydroxyl groups on car-
bons 6′ and 3′ of the glucopyranose moiety and the sidechains of S59 and S60 (Fig. 2C). The main chain nitrogen 
of V61 may also make an interaction with the hydroxyl group on carbon 4′. In contrast, with ginsenoside Rd it is 
the disaccharide moiety attached to carbon-3 which is predicted to interact with the hP2X7 central vestibule glu-
cose subsite, suggesting an inverted mode of binding compared to CK. None of the docking results for Rd placed 
the single glucopyranose moiety attached to carbon-20 within the putative binding site. Additional interactions 
were observed with docking of Rd to hP2X7, particularly stacking of the hydrophobic α-face of a glucose moiety 
onto the side chain of L320 (Fig. 1). Hydrophobic residues within the β-sheets likely enhance the interaction with 
the steroid backbone of the ginsenosides. In general, due to its smaller size CK may fit deeper within the cleft and 
this may explain its superior activity at hP2X7 compared to Rd. Furthermore, CK is more rigid than Rd and thus 
CK binding may involve a smaller entropic penalty.
Selected amino acid residues in these identified regions of the putative binding site on hP2X7 were then 
mutated using site-directed mutagenesis (S59, S60, N100, S101, D318, and L320) and the mutant hP2X7 recep-
tors were stably expressed in HEK-293 cells. The G99EE mutant was generated to mimic the sequence found in 
human P2X4 receptors (QEENS) vs human P2X7 (QGNS) (Fig. 2D) since P2X4 can also be potentiated by gin-
senosides25. Flow cytometry analysis indicated all the mutant hP2X7 receptors were expressed at the cell surface, 
although at lower levels than wild-type hP2X7 (Fig. S2).
Loss of ginsenoside-induced potentiation of hP2X7 carrying D318 or L320 central vestibule 
mutations. Activation of hP2X7 results in the formation of a large reversible secondary pore which allows 
Figure 2. Ginsenoside binding pocket consists of interactions with D318, N100 and S60 residues in hP2X7 
lower body region. (A) An individual subunit is displayed with two lower body region β-sheets highlighted in 
magenta (β2 and β14). CK is shown docked into the putative binding site. Rotation of this individual subunit by 
90° allows better visualisation of the internal loop containing N100 that is predicted to make contact with the 
glucopyranose ring of ginsenoside CK. (B) Trimeric view of the hP2X7 model showing the docked ginsenoside 
connecting inter-subunit β-sheets β2 (magenta) and β14 (salmon pink). (C) Closer view of the docked 
ginsenoside CK displaying interacting residues predicted to make polar contacts; D318, N100 and S60.
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cell impermeant large cationic molecules (such as the fluorescent dye YOPRO-1) to enter the cells, bind to DNA 
and fluoresce5. Stimulation with ATP resulted in uptake of YOPRO-1 by all hP2X7 mutants. N100A, N100W, 
S101A and G99EE mutations in hP2X7 resulted in poorer dye uptake responses to ATP (Fig. 3B). Conversely, 
the S60A, D318L, and D320A mutations in hP2X7 resulted in YOPRO-1 responses with increased sensitiv-
ity to ATP (Fig. 3A,B). Following the simultaneous addition of ATP plus CK, or ATP plus Rd, 3.82 ± 1.02 and 
2.14 ± 0.21 fold increases respectively in WT hP2X7-dependent YOPRO-1 uptake were observed (Fig. 3C). 
Calculating fold-potentiation elicited by CK and Rd on the ATP responses demonstrated that ginsenoside poten-
tiation of N100A, N100W, S101A, and G99EE mutations was enhanced compared to WT hP2X7, although this 
only reached statistical significance for the G99EE mutation (Fig. 3C). Notably, S60A, D318L, L320A mutations 
resulted in a complete loss of CK or Rd potentiation of ATP-dependent dye uptake responses (Fig. 3B,C). S59A 
and D318A mutants showed reduced potentiation by CK or Rd. The control ginsenoside, the aglycone proto-
panaxadiol (PPD) did not result in potentiation of ATP responses at WT hP2X7 or any of the hP2X7 mutants 
(Fig. 3C). We confirmed that ginsenoside potentiation was abolished for the D318L, L320A, S60A mutants when 
BzATP (30 µM) was used as the agonist and observed the same general trend as with ATP-induced dye uptake 
responses (Fig. S3A–C). Furthermore, ATP and BzATP-induced dye uptake responses at WT, S60A, D318L, and 
L320A hP2X7 could be inhibited by the selective P2X7 antagonist AZ10606120 (Fig. S4) and responses induced 
by agonist plus PAM could also be inhibited by AZ10606120. The exception to this was D318L mutant where 
BzATP + CK responses could not be inhibited by AZ10606120 (Fig. S4).
Figure 3. Mutations within the predicted ginsenoside binding site abolish potentiation of P2X7-dependent 
dye uptake and sustained Ca2+ responses. (A) ATP-induced dye uptake into HEK-P2X7 cells was measured 
at 37 °C using a fluorescent plate reader (Flexstation 3). YOPRO-1 (2 µM) was the membrane impermeant 
dye, all compounds were prepared in DMSO and experiments were performed in low divalent cation buffer. 
Representative dye uptake fluorescence traces for hP2X7 mutants vs WT following stimulation with 200 µM 
ATP plus DMSO (black), ATP plus 10 µM CK (pink) or ATP plus 10 µM Rd (green). (B) pEC50 values were 
determined for WT P2X7 and mutants following stimulation with a range of ATP concentrations (10 µM to 
2 mM) using YOPRO-1 responses measured as area under curve (50–300 seconds). (C) Fold-potentiation was 
calculated with respect to the ATP control response using AUC data from 3 independent experiments. (D) ATP-
induced intracellular Ca2+ responses were measured at 37 °C using Fura-2AM loaded cells. Fold-potentiation of 
the sustained phase of the ATP-induced calcium response was calculated by taking mean Fura-2 ratio between 
150–300 seconds. The ginsenoside aglycone PPD was included as a negative control. Error bars represent SEM, 
*P < 0.05.
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Due to the low dye uptake responses to agonists in several hP2X7 mutants we next tested ginsenoside potenti-
ation of intracellular Ca2+ responses using fura-2AM loaded cells. Stimulation with either ATP or BzATP resulted 
in a transient peak response followed by a sustained increase in intracellular calcium (Figs S5A,B and S6A–C) 
as previously demonstrated13. CK and Rd induced a 2.10 ± 0.70 and 2.19 ± 0.16 fold increase in ATP-dependent 
sustained Ca2+ response in HEK-hP2X7, respectively. In agreement with the dye uptake data, effects of ginseno-
sides were amplified for the G99EE, N100A, N100W, and S101A mutations (Fig. 3D). S60A, D318L, and L320A 
mutations were again observed to be more sensitive to lower concentrations of ATP (Fig. S5A,B) and potentiation 
of ATP-induced intracellular Ca2+ responses by CK and Rd was dramatically reduced/abolished in S59A, S60A, 
D318L, and L320A mutants (Fig. 3D). To rule out the possible saturation of the fura-2 dye in S59A and L320A 
mutant responses, we repeated the experiments using a lower concentration of ATP (50 µM) and saw a similar 
effect; greatly reduced potentiation of ATP responses by CK (Fig. S7).
Mutations S60A, D318L and L320A affect P2X7 sensitivity to agonist. Unexpectedly we found 
that mutating key residues predicted to interact with ginsenosides generated P2X7 receptors that were better able 
to respond to ATP or BzATP (Figs 3A–D and S3A–C). This was confirmed using whole cell patch clamp analysis 
of ATP responses and peak amplitudes were up to 5-fold larger in the S60A mutant (Fig. 4A). Responses to ATP 
(100 µM) could be completely inhibited by 300 nM AZ10606120 (Fig. 4C) in WT, D318L and L320A, however, 
S60A responses appeared to be somewhat less sensitive to this antagonist (Fig. 4C).
Patch clamp recordings revealed a much larger potentiation of ATP-induced inward currents by ginsenosides 
at WT hP2X7 than was estimated using the dye uptake and calcium measurements. CK and Rd potentiated ATP 
responses in WT hP2X7 cells by 27.61 ± 4.07 fold and 17.82 ± 6.51 fold respectively (Fig. 5A–C). Fold potenti-
ation of ATP responses (100 µM) by CK and Rd was significantly reduced in S60A, D318L, and L320A mutants 
(Fig. 5A–C) as were BzATP-induced responses (Fig. S8). We also found that patch clamp recordings could better 
distinguish between CK-mediated and Rd-mediated potentiation of ATP-induced responses; G99EE, N100A, 
N100W, and S101A hP2X7 mutants demonstrated enhanced potentiation to CK but reduced potentiation by Rd 
(Fig. 5A–C). This may be due to the rapid delivery of agonist plus PAM to the cell and the inability of Rd to bind 
optimally during this timeframe.
Ginsenoside binding enhances P2X7-mediated cell death. P2X7 is well known to be involved in 
the regulation of cell death26 and our previous work has demonstrated that CK enhances P2X7-dependent cell 
death in J774 murine macrophages13. We first determined whether S60A, D318L, and L320A mutants were more 
Figure 4. Patch clamp analysis reveals altered agonist responses in D318L, L320A and S60A mutants. Whole 
cell patch clamp recordings were performed at room temperature. Cells were voltage-clamped at −60 mV and 
responses to 5 second application of ATP (100 µM) measured from HEK-293 cells stably expressing WT or 
mutant hP2X7. (A) Representative traces are shown for ATP responses (B) Summary of normalised current 
amplitudes expressed as pA/pF (n = 5–25 cells). (C) Inhibition by AZ10606120 (30 nM, 300 nM) was tested in 
cells expressing D318L, S60A and L320A hP2X7 mutants and compared to WT hP2X7. An initial response to 
ATP was measured and then AZ10606120 applied to the cell for 1 minute followed by ATP in the presence of 
AZ10606120. Traces are representative of 3–5 cells.
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susceptible to ATP-induced cell death using an AlamarBlue cell viability assay (Fig. 6A). Cells expressing WT 
hP2X7 or S59A were killed by ATP concentrations >1 mM whereas S60A, D318L, and L320A mutants started 
to show reduced cell viability at ATP concentrations as low as 100 μM (Fig. 6A). AZ10606120 could inhibit cell 
death induced by 3 mM ATP in all cases (Fig. 6A–C). We have demonstrated that ginsenoside CK can induce cell 
death in combination with a non-lethal concentration of ATP (500 µM) in HEK-hP2X7 cells25. Here we show that 
CK in combination with ATP could reduce the viability of cells expressing WT hP2X7 or S59A-P2X7 and this was 
reversed by incubation with AZ10606120 (Fig. 6B). CK could still enhance cell death in the S60A mutant to ATP 
concentrations as low as 100 μM (Fig. 6C) likely due to retention of some potentiating action of CK at this mutant 
(5.88 ± 6.36 fold, Fig. 5). However, we found that CK could not enhance cell death in D318L or L320A P2X7 
mutant cells (Fig. 6C) to various concentrations (50 μM, 100 μM, 500 μM) of ATP demonstrating that eliminating 
critical interacting residues on hP2X7 abolished all of the PAM effects of ginsenoside CK.
Discussion
The main finding of this study is the identification of a putative binding site for ginsenosides located within the 
central vestibular region of P2X7 (Movie S1). This is the first PAM binding site to be described on the P2X7 
receptor and furthermore, it is the first binding site to be identified within the central cavity (vestibule) of the 
P2X channel. Through targeted site-directed mutagenesis we have demonstrated that mutation of specific amino 
residues, namely the D318L, and L320A mutations within the lower body β-sheet region resulted in abolish-
ment of CK and Rd effects on P2X7-dependent pore formation. Moreover, the D318L and L320A mutations 
resulted in abrogated Ca2+ influx and ATP-induced P2X7 channel opening. Furthermore, mutating the D318 and 
L320 residues was cytoprotective against the combined effects of ATP and CK at concentrations observed to kill 
HEK-hP2X7 cells.
Since the crystal structure of zfP2X4 in the apo and ATP bound states were published19,23, many studies have 
used homology models to predict the three-dimensional structure of other P2X receptors. The region we have 
investigated is the central vestibule which is accessed through the lateral portals, the proposed ion conduction 
pathway for P2X channels27. The β-sheet structures β-2 and β-14 from adjacent subunits in the trimeric P2X 
structure line the surface edge of these portals and additionally connect the ATP binding site to the transmem-
brane domains28. Upon ATP binding, rotational movements are thought to occur closing the ‘jaw’ around the 
agonist and allowing outward movement (flexing) of the edges of the lateral portals, widening the central ves-
tibule19. We propose that upon opening of the P2X7 channel, a PAM binding site is revealed within the central 
vestibule and co-ordination of a chemical containing a glucopyranose moiety culminates in potentiation of the 
agonist-triggered response. Binding of the ginsenoside chemicals may stabilise the open state or may provide an 
Figure 5. Electrophysiology reveals differences between CK and Rd potentiation of P2X7. (A) HEK-hP2X7 and 
central vestibule mutants were voltage clamped at −60 mV and either ATP alone (100 µM), ATP + CK (10 µM), 
or ATP + Rd (10 µM) was rapidly applied for 5 seconds prior to wash off. Traces are representative of 5–9 cells. 
(B) Summary of normalised current amplitudes expressed as pA/pF (n = 5–9 cells). (C) Potentiation of ATP 
responses by CK and Rd expressed as fold potentiation (normalised to ATP alone).
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enhanced movement of the connecting rods (β-sheets linking the ATP binding to TM movement). Roberts et al. 
demonstrated that locking of the β-sheets across the lateral portal by forcing a disulphide bridge between 60 C and 
320 C in hP2X1 channels, inhibited channel responses to ATP29. Breaking this forced bridge using DTT effectively 
reversed the lock29. In addition, Samways et al. have demonstrated that certain residues in the central vestibule 
β-sheet region of hP2X4 were amenable to modification with MTSET+ 27. S59 and S62 (hP2X4 numbering) were 
mutated to cysteine residues and application of MTSET+ caused potentiation of ATP-responses at these mutant 
P2X4 channels. This suggests that residues in the lower body β2 sheet are accessible via lateral portals and that 
modifications can positively affect channel gating27.
There are few well described positive allosteric modulators of P2X channels. Within the family, ivermectin 
is best characterised for its actions on P2X4 and there is some evidence for PAM action in the region of the 
lateral portals. The binding site for ivermectin is thought to be much lower, residing within the transmembrane 
helices30. W46 and W50 in TM1 and D331 and M336 (rat P2X4 numbering) in TM2 are thought to contribute 
to the ivermectin binding site31 although residues E56 and D58 (hP2X4 numbering) may also contribute to the 
allosteric binding site for ivermectin27. Ivermectin is also thought to potentiate human P2X7 receptors32 but 
there is no evidence as yet whether this is due to interaction with a similar transmembrane binding site to P2X4. 
The possibility exists that ivermectin may bind to a site overlapping the ginsenoside site in the central vestibule 
however the following pieces of data may argue against this; firstly, ivermectin could not potentiate YOPRO-1 
responses32 whereas ginsenosides can effectively potentiate YOPRO-1 responses (Fig. 3) and secondly, the poten-
tiating effects of ivermectin were much smaller than the ginsenosides. Ivermectin is thought to have an effect on 
calcium permeability through the P2X4 channel (reducing the fractional calcium current, Pf%) and removal of 
the charged residue E51 at the top of TM1 abolished this effect33. Whilst we have not measured Pf% through P2X7 
in this study, it is unlikely that ginsenosides affect calcium permeability due to the predicted binding site sitting 
well away from the transmembrane regions. We have measured sustained calcium levels in P2X7 expressing HEK 
cells and show that CK and Rd can significantly increase intracellular calcium levels (Fig. 4). Effects on membrane 
Figure 6. D318L and L320A mutations abolish the potentiating effect of CK on ATP-induced cell death. 
Cells were seeded at 5 × 103 in a 96-well plate 24 h prior to stimulation with a range of ATP concentrations 
(1 µM–3 mM) or 3 mM ATP + AZ10606120 (10 µM) for a further 24 h. AlamarBlue was added for 2 h prior to 
measurement of fluorescence (RFU) using a Flexstation 3 plate reader. (A) Data is presented as the percentage 
mean cell viability compared to control media. (B) Cell viability was determined in the presence of 500 μM 
ATP + CK compared to 500 μM ATP alone for WT hP2X7 and S59A hP2X7. (C) Cell viability was determined 
in the presence of 50 μM ATP + CK, 100 μM ATP + CK, and 500 μM ATP + CK compared to each concentration 
of ATP alone for WT hP2X7, S60A, D318L and L320A hP2X7 mutants.
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currents in cells clamped at −60 mV were also significant (Fig. 6) suggesting ginsenosides may increase cation 
conductance. This will potentially translate to changes in membrane potential which could be important in mye-
loid cells where ion fluxes (K+, Ca2+) may contribute to the activation of the NLRP3 inflammasome34.
Our finding that S60A, D318L, and L320A mutations created hP2X7 receptors with larger responses and 
higher sensitivity to ATP was somewhat unexpected. The overlap with these residues being highlighted as crit-
ical interacting residues with ginsenosides CK and Rd is unlikely to be coincidence and is suggestive that these 
residues make a difference to the ease of opening of the channel in response to agonist binding. Patch clamp 
data suggests the kinetics of channel opening are similar and there is no apparent difference in deactivation 
kinetics (Fig. 4A). Indeed, the already enhanced P2X7 activity in S60A mutant may underlie the reduction in 
ginsenoside-induced potentiation in this mutant. There is likely an upper limit to the movement of the β-sheets 
connecting the agonist binding site to the transmembrane domains. Furthermore, the altered sensitivity to 
AZ10606120 may reflect the amount of antagonist required to reverse the opening of this mutant channel.
Measuring the effects of the ginsenosides using whole cell patch clamp recordings revealed larger levels 
of potentiation of ATP responses than were shown in the plate reader fluorescence experiments (YOPRO-1, 
Ca2+). Additionally, these experiments exposed a difference between the potentiating effects of CK and Rd on 
the mutants. Partly this may be due to the co-exposure of the channel to agonist (ATP) plus ginsenoside for only 
5 seconds before the agents were washed away. All of the mutants were poorly potentiated by Rd in comparison 
to CK (Fig. 6). This may be due to the strength and speed of binding of the modulators to the predicted central 
vestibule site. Ginsenoside CK being smaller than Rd and making more predicted interactions with lower body 
β-sheets, may bind better to the open state of the human P2X7 channel.
Our data on modulation of P2X7-induced cell death demonstrates that it is possible to enhance cell death with 
a positive allosteric modulator of P2X7. These experiments were performed over 24 hours, much longer than the 
immediate effects of channel activation and therefore show that modulation of channel activity can be translated 
into downstream outcomes. We confirmed that certain mutations (S59A, S60A, L320A) enhanced the sensitivity 
of P2X7 to ATP by showing reduced cell viability at low ATP concentrations (Fig. 6A). The S60A mutation did 
not completely abolish ginsenoside potentiation in the patch clamp experiments (Fig. 5A) and similarly, we still 
observed a potentiation in ATP-induced cell death in these cells. Importantly we observed that the D318L and 
L320A mutants were resistant to potentiation by CK confirming the lack of modulation of P2X7 channel activity 
in fluorescence/electrophysiology experiments.
In conclusion, the identification of a modulator binding site on P2X7 opens up new potential therapeutic ben-
efits for disorders linked to dysfunctional P2X7 responses such as the defective killing of intracellular pathogens 
associated with loss-of-function polymorphisms in P2X735–37. Furthermore, potentiators acting at this site might 
also be useful in inducing apoptotic cell death in tumour cells. It is also possible that we may be able to design 
antagonists to bind to this novel binding site potentially generating a series of open channel blockers to increase 
drug discovery opportunities for this important P2X receptor.
Materials and Methods
Cell culture. HEK-293 cells stably transfected with wild-type or mutant human P2X7 (hP2X7) receptors 
(EE-tagged hP2X7 in pcDNA3.1 plasmid) were maintained in DMEM/F-12 media containing L-glutamine (Life 
Technologies, Fisher Scientific) supplemented with 10% FBS (South American origin, Gibco), 10000 U mL−1 
penicillin and 10 mg mL−1 streptomycin (Life Technologies, Fisher Scientific) with selection under 400 μg mL−1 
G418 (Life Technologies, Fisher Scientific). All cells were maintained at 37 °C in a 5% CO2 humidified incubator.
Mutagenesis. Point mutations were introduced into the WT hP2X7 plasmid using the Stratagene 
Quikchange II site-directed mutagenesis kit (Agilent Technologies). Primers were purchased from Sigma Aldrich. 
PCR was performed for 16–18 cycles using Pfu turbo polymerase and products digested with DpnI for 1 hour at 
37 °C. NEB 5-alpha F’Iq competent E.coli high efficiency cells (New England Biolabs, UK) were transformed with 
5 µl of digested product and colonies selected following growth at 37 °C for 16 hours. Plasmids were extracted 
using Qiagen miniprep kit and mutations verified by sequencing (Eurofins Genomics).
Flow cytometry. To quantify cell surface expression of hP2X7, 1 × 105 cells were pelleted prior to resus-
pension in primary mouse anti-hP2X7 antibody (clone L4, a kind gift from Associate Professor Ronald Sluyter, 
University of Wollongong, Australia) at a dilution of 1:100 in PBS/0.5% BSA buffer. Cells were incubated for 
1 hour on ice. Following a washing step, cells were resuspended in secondary goat anti-mouse IgG AlexaFluor 488 
(Fisher Scientific) at a dilution of 1:100 and incubated in the absence of light for 1 h on ice. Cells were washed and 
fluorescence was measured on a CytoFLEX flow cytometer (Beckman Coulter; laser excitation, 488 nm; emission 
detection, 533/30 nm). Data was analysed using CytExpert software (Beckman Coulter; version 2.1). All washes 
were conducted in PBS containing 0.5% (w/v) BSA at 300 g for 5 mins.
Dye uptake experiments. Cells were plated at 2.5 × 104 cells per well the day before experiments into 
poly-D-lysine (Millipore) coated 96-well plates (NUNC, Fisher Scientific). The membrane impermeant dye 
YOPRO-1 iodide (Life Technologies, Fisher Scientific) was used at a final concentration of 2 μM in low divalent 
buffer (145 mM NaCl, 5 mM KCl, 0.2 mM CaCl2, 13 mM glucose, 10 mM HEPES, pH 7.3, osm 300–310). Data 
was acquired on a Flexstation 3 plate reader (Molecular Devices) using excitation wavelength 490 nm, emis-
sion wavelength 520 nm and 6 reads per well. ATP ± ginsenosides at 10X final concentration was automatically 
injected at 40 seconds from a 96-well V-bottomed drug plates (Greiner). Pipette height was set to 180 µl and the 
rate of injection was 4. Data was analysed as AUC between 50 and 300 seconds using SoftMax Pro v5.4 software 
(Molecular Devices).
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Calcium measurements. Cells were plated at 2.5 × 104 cells per well the day before experiments into 
poly-D-lysine coated 96-well plates. Cells were loaded with 2 μM Fura-2-acetoxymethyl (AM) calcium indicator 
dye (Hello Bio, UK) in standard HBSS buffer containing 250 µM sulfinpyrazone for 40 minutes at 37 °C. This load-
ing buffer solution was removed and replaced with standard low divalent buffer containing 250 µM sulfinpyra-
zone. A Flexstation 3 plate reader was used to acquire data using dual excitation wavelengths 340 nm and 380 nm 
with an emission wavelength of 520 nm, 3 reads per well. ATP ± ginsenosides/vehicle at 10X final concentration 
was injected after 40 seconds. Data was analysed as AUC between 150 seconds and 300 seconds using SoftMax Pro 
software (Molecular Devices).
Patch-clamp electrophysiology. Stably expressing HEK-hP2X7 cells were plated onto 13 mm glass cover-
slips 24 hours prior to use. Membrane currents were recorded in the whole-cell patch-clamp configuration using 
an EPC10 amplifier (HEKA Elektronik) and borosilicate glass electrodes (TF-150 World Precision Instruments), 
resistance 3–8 Ω when filled with standard internal solution (145 mM NaCl, 10 mM HEPES, 10 mM EGTA, pH 
7.3). Cells were voltage clamped at −60 mV and dialysis of intracellular contents was performed for 1 minute 
prior to experimental procedures. Cells were continuously perfused by gravity feed with standard divalent buffer 
solution (145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 13 mM glucose, 10 mM HEPES, pH 7.3) prior to 
seal formation, and low divalent buffer solution was used for agonist and PAM application in most experiments. 
Agonists were applied using a computer-controlled fast-flow system (RSC-160; Bio-Logic Scientific Instruments) 
with the perfusion capillaries placed in close proximity to the cell under investigation.
Cell viability assays. Cells were plated at 5 × 103/well in Nunc Edge 96-well plates (Scientific Lab Supplies, 
UK) 24 hours prior to stimulation with increasing concentrations of ATP (1 μM–3 mM), or a combination of ATP 
and CK (500 μM and 10 μM, respectively) in the presence or absence of AZ10606120 (10 μM), for 24 h. Following 
incubation, resazurin (0.1 mg/ml in PBS, Sigma Aldrich) was added to cells for 2 h at 37 °C and fluorescence was 
measured on a Flexstation 3 plate reader (laser excitation, 570 nm; emission detection, 600 nm).
P2X7 homology model. The coordinates of zfP2X4 in the ATP-bound open state (PDB: 4DW1) were used 
as a template. The sequence of human P2X7 was aligned to the template using the ClustalW algorithm38. The 
Schrödinger Prime software was used to construct an energy-based all-atom model with the OPLS3 forcefield, 
keeping the ATP coordinates from the template. Regions of low sequence homology were refined using extended 
serial loop sampling in the Prime software.
Induced fit docking. Three-dimensional models of the ginsenosides CK and Rd were generated using the 
LigPrep software within the Schrödinger Maestro suite. The OPLS3 forcefield was used to generate 32 low-energy 
conformers for each ginsenoside. Induced fit docking was performed using the automated extended sampling 
protocol in the Schrödinger Maestro suite. This first performed several initial docking runs, in which sidechains 
were either trimmed, or their van der Waals potentials softened according to their flexibility. Side chains were 
then rebuilt and those within 5 Å of the ligand were optimised using Prime39. Ligands were then re-docked to the 
new receptor structure using the Glide SP algorithm40 and standard potentials. Structures within 30 kcal mol−1 of 
the lowest energy structure were retained.
The receptor grid was centred on the highest-scoring potential binding site, found using Sitemap41, and had a 
cubic box with dimensions of 30 Å. Each of the 32 conformers were docked using the extended sampling protocol. 
For each ginsenoside, the resulting poses were clustered by heavy atom RMSD using the average-linkage method, 
and a representative structure was chosen from the model closest to the centroid of the most populated cluster. 
For CK and Rd the most populated cluster made up 27% and 59% of all solutions respectively.
Data analysis. All graphs were plotted and statistical tests performed using GraphPad Prism v7. Significance 
was taken as P < 0.05.
Data Availability
The data generated during the current study are available from the corresponding author on reasonable re-
quest. Molecular models of P2X7 are available at https://bit.ly/2DhW2fF.
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